Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Collplant Holdings ( (CLGN) ) has provided an update.
CollPlant Biotechnologies Ltd. announced that it has successfully transferred the listing of its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective September 12, 2025. This move is part of the company’s strategic efforts to optimize its market positioning while maintaining the trading symbol ‘CLGN’. The transfer is expected to have no impact on the trading of its shares, ensuring continuity for investors and stakeholders.
The most recent analyst rating on (CLGN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
Collplant Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by significant revenue and cash flow declines and negative profit margins. Technical analysis provides a neutral outlook, while valuation metrics indicate potential overvaluation due to negative earnings. The lack of earnings call and corporate events data limits further insights.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies Ltd. operates in the biotechnology industry, focusing on developing innovative products for tissue regeneration and organ manufacturing. The company is known for its plant-based collagen technology, which is used in various medical applications.
Average Trading Volume: 60,990
Technical Sentiment Signal: Sell
Current Market Cap: $34.46M
See more data about CLGN stock on TipRanks’ Stock Analysis page.